Trial
NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
National Cancer Institute (NCI)
Condition
Chronic Lymphocytic Leukemia
Intervention
Lenalidomide, Ibrutinib, Rituximab
Why stopped
Recruitment difficulties and toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-12